EP2364699A1 — Joint use of sulfonamide based compound with angiogenesis inhibitor
Assigned to Eisai R&D Management Co Ltd · Expires 2011-09-14 · 15y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising a sulfonamide-including compound in combination with a VEGF receptor kinase inhibitor as an angiogenesis, inhibitor, wherein the sulfonamide-including compound is N-(3-cyano-4-methyl-1 H-indol-7-yl)-3-cyano…
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising a sulfonamide-including compound in combination with a VEGF receptor kinase inhibitor as an angiogenesis, inhibitor, wherein the sulfonamide-including compound is N-(3-cyano-4-methyl-1 H-indol-7-yl)-3-cyanobenzenesulfonaxnide (E7820), or a pharmacologically acceptable salt thereof or a solvate thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.